Stock MBRX MOLECULIN BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Moleculin Biotech, Inc.

Equities

MBRX

US60855D3098

Delayed Nasdaq
Other stock markets
 03:09:24 2024-04-29 pm EDT 		5-day change 1st Jan Change
5.02 USD +8.42% Intraday chart for Moleculin Biotech, Inc. +16.74% -61.01%
Apr. 18 Sector Update: Health Care Stocks Ease in Afternoon Trading MT
Apr. 18 Moleculin Biotech Secures Orphan Drug Label For Annamycin in EU MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
European Medicines Agency Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia
AQ
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
PR
Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
PR
Moleculin to Participate in the Virtual Investor Lunch Break, the Moleculin Opportunity
AQ
Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
PR
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
PR
Moleculin Reports Full Year 2023 Financial Results
AQ
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
PR
Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast
PR
Moleculin Announces Reverse Stock Split
PR
Moleculin to Present at the 36th Annual ROTH Conference
PR
Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3
PR
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
PR
Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL s in Conjunction with ASH Annual Meeting
AQ
Virtual Investor: What this Means - Form 8-K
PU
Moleculin Announces Positive Interim Data in Annamycin Clinical Trials, MB-106 AML Trial Complete Response Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months
AQ
Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months
PR
Moleculin Reports Third Quarter 2023 Financial Results
PR
Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast
PR
Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas Lung Metastases
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MBRX Stock
  4. News Moleculin Biotech, Inc.
  5. Press Releases